(2E,4E,8S,10S,13S,14S,17R,18S,19R)-4-ethyl-13,17-dihydroxy-19-((R)-3-hydroxy-3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoyloxy)-8,10,14,18-tetramethyl-15-oxoicosa-2,4-dienoic acid

ID: ALA3718369

Chembl Id: CHEMBL3718369

PubChem CID: 46236470

Max Phase: Preclinical

Molecular Formula: C34H52O11

Molecular Weight: 636.78

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCC(/C=C/C(=O)O)=C\CC[C@H](C)C[C@@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@H](C)[C@@H](C)OC(=O)C[C@@H](O)C1=C(C)C(=O)OC1=O

Standard InChI:  InChI=1S/C34H52O11/c1-8-25(13-15-30(39)40)11-9-10-19(2)16-20(3)12-14-26(35)22(5)28(37)17-27(36)21(4)24(7)44-31(41)18-29(38)32-23(6)33(42)45-34(32)43/h11,13,15,19-22,24,26-27,29,35-36,38H,8-10,12,14,16-18H2,1-7H3,(H,39,40)/b15-13+,25-11+/t19-,20-,21+,22-,24+,26-,27+,29+/m0/s1

Standard InChI Key:  SBYRDFXBMBXOAD-HHUJSAGPSA-N

Alternative Forms

1. Parent:

   

   ALA3718369

   (2E,4E,8S,10S,13S,14S,17R,18S,19R)-4-ethyl-13,17-dihydroxy-19-[(3R)-3-hydroxy-3-(4-methyl-2,5-dioxofuran-3-yl)propanoyl]oxy-8,10,14,18-tetramethyl-15-oxoicosa-2,4-dienoic acid

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 636.78

Molecular Weight (Monoisotopic): 636.3510

AlogP: 4.22

#Rotatable Bonds: 21

Polar Surface Area: 184.73

Molecular Species: ACID

HBA: 10

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.87

CX Basic pKa: ┄

CX LogP: 5.29

CX LogD: 2.80

Aromatic Rings: ┄

Heavy Atoms: 45

QED Weighted: 0.06

Np Likeness Score: 1.80

References

1.  (2012)  Tautomycetin and Tautomycetin analog biosynthesis, 

Source

Source(1):

• Patent Bioactivity Data